Pharmacotherapy for pediatric soft-tissue sarcomas

Bibliography

• Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo PA, Poplack DG, editors, Principles and practice of pediatric oncology. 5th edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2006. p. 971-1001
   Google Scholar
• Okcu MF, Hicks J, Merchant TE, Nonrhabdomyosarcomatous soft tissue sarcomas. In: Pizzo PA, Poplack DC, editors, Principles and practice of pediatric oncology. 5th edition. Lippincott Williams & Wilkins, Philadelphia; 2006. p. 1033-73
   Google Scholar
• Gurney JG, Young JL Jr, Roffers SD, Soft tissue sarcomas, in: cancer incidence and survival among children and adolescents: United States SEER Program 1975-1999. National Cancer Institute Publication. Available from: http://seer.cancer.gov/publications/childhood/softtissue.pdf
   Google Scholar
• Meyer WH, Spunt SL. Soft tissue sarcoma of childhood. Cancer Treat Rev 2004;30:269-80
   PubMed Web of Science ®Google Scholar
• Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123-39
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev Anticancer Ther 2005;5:283-94
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. New concepts for the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2005;5:307-18
   PubMed Web of Science ®Google Scholar
• Spunt SL, Poquette CA, Hurt YS, Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol 1999;17:3697-705
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M, Meazza C, Adult-type soft tissue sarcomas in pediatric age: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol 2005;23:4021-30
   PubMed Web of Science ®Google Scholar
• Stevens MC. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 2005;6:77-84
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Anderson J, Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment – results of an international workshop. J Clin Oncol 2001;19:197-204
   PubMed Web of Science ®Google Scholar
• Defachelles AS, Rey A, Oberlin O, Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from International Society of Pediatric Oncology studies MMT 89 and 95. J Clin Oncol 2009;27:1310-5
   PubMedGoogle Scholar
• Maurer HM, Beltangady M, Gehan EA, The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988;61:209-20
   PubMed Web of Science ®Google Scholar
• Carli M, Pastore G, Perilongo G, Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J Clin Oncol 1988;6:654-8
   PubMed Web of Science ®Google Scholar
• Crist WM, Anderson JR, Meza JL, Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102
   PubMed Web of Science ®Google Scholar
• Spunt SL, Smith LM, Ruymann FB, Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin Cancer Res 2004;10:6072-9
   PubMed Web of Science ®Google Scholar
• Bergeron C, Thiesse P, Rey A, Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer 2008;44:427-31
   PubMedGoogle Scholar
• Stevens MC, Rey A, Bouvet N, Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology -SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23:2618-28
   PubMed Web of Science ®Google Scholar
• Crist W, Gehan EA, Ragab AH, The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610-30
   PubMed Web of Science ®Google Scholar
• Womer RB. The Intergroup Rhabdomyosarcoma Studies come of age. Cancer 1993;71:1719-21
   PubMedGoogle Scholar
• Arndt CA, Hawkins DS, Meyer WH, Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;50:33-6
   PubMedGoogle Scholar
• Bisogno G, Ferrari A, Bergeron C, The IVADo regimen – a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study on behalf of the European pediatric Soft tissue sarcoma Study Group. Cancer 2005;103:1719-24
   PubMed Web of Science ®Google Scholar
• Lager JJ, Lyden ER, Anderson JR, Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006;24:3415-22
   PubMedGoogle Scholar
• Blaney SM, Needle MN, Gillespie A, Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res 1998;4:357-60
   PubMed Web of Science ®Google Scholar
• Nitschke R, Parkhurst J, Sullivan J, Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998;20:315-18
   PubMed Web of Science ®Google Scholar
• Pappo AS, Lyden E, Breneman J, Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2001;19:213-19
   PubMed Web of Science ®Google Scholar
• Saylors RL III, Stine KC, Sullivan J, Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-9
   PubMed Web of Science ®Google Scholar
• Arndt CA, Stoner JA, Hawkins DS, Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol 2009;27:5182-8
   PubMed Web of Science ®Google Scholar
• Bisogno G, Riccardi R, Ruggiero A, Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006;106:703-7
   PubMed Web of Science ®Google Scholar
• Pappo AS, Lyden E, Breitfeld P, Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 2007;25:362-9
   PubMedGoogle Scholar
• Mascarenhas L, Lyden ER, Breitfeld PP, Randomized phase II window study of two schedules of irinotecan (CPT-11) and vincristine (VCR) in rhabdomyosarcoma (RMS) at first relapse/disease progression. J Clin Oncol 2008;26(15 Suppl): abstract 10013
   Google Scholar
• Furman WL, Crews KR, Billups C, Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006;24:563-70
   PubMed Web of Science ®Google Scholar
• Ferraldeschi R, Minchell LJ, Roberts SA, UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics 2009;10:733-9
   PubMed Web of Science ®Google Scholar
• Furman WL, Navid F, Daw NC, Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009;27:4599-604
   PubMed Web of Science ®Google Scholar
• Pourquier P, Waltman JL, Urasaki Y, Topoisomerase I-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosogunidine: trapping of topoisomerase I by the O6-methylguanidine. Cancer Res 2001;61:53-8
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Stewart CF, Cheshire PJ, Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and misnatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-18
   PubMed Web of Science ®Google Scholar
• Raney RB, Anderson JR, Barr FG, Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001;23:215-20
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Lyden E, Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008;26:2384-9
   PubMed Web of Science ®Google Scholar
• Koscielniak E, Klingebiel TH, Peters C, Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997;19:227-31
   PubMed Web of Science ®Google Scholar
• Carli M, Colombatti R, Oberlin O, High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol 1999;17:2796-803
   PubMed Web of Science ®Google Scholar
• Weigel BJ, Breitfeld PP, Hawkins D, Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001;23:272-6
   PubMed Web of Science ®Google Scholar
• Bisogno G, Ferrari A, Prete A, Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. Eur J Cancer 2009;45:3035-41
   PubMedGoogle Scholar
• Donker AE, Hoogerbrugge PM, Mavinkurve-Groothuis AM, Metastatic rhabdomyosarcoma cured after chemotherapy and allogeneic SCT. Bone Marrow Transplant 2009;43:179-80
   PubMedGoogle Scholar
• Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000;36:87-94
   PubMed Web of Science ®Google Scholar
• Weigel B, Lyden E, Anderson JR, ; Early results from Children's Oncology Group (COG) ARST0431. Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). J Clin Oncol 2010;28(15 Suppl): abstract 9503
   PubMedGoogle Scholar
• Casanova M, Ferrari A, Spreafico F, Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer 2002;94:3263-8
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A, Bisogno G, Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 2004;101:1664-71
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Boos J, Beske F, Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer 2008;50:739-45
   PubMed Web of Science ®Google Scholar
• Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010, doi:10.1016/j.ctrv.2010.02.007
   Google Scholar
• Zwaan CM, Kearns P, Caron H, The role of the ‘innovative therapies for children with cancer’ (ITCC) European consortium. Cancer Treat Rev 2010, doi:10.1016/j.ctrv.2010.02.008
   Google Scholar
• Houghton PJ, Adamson PC, Blaney S, Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 2002;8:3646-57
   PubMed Web of Science ®Google Scholar
• Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001;11:289-97
   PubMedGoogle Scholar
• Minniti CO, Tsokos M, Newton W Jr, Helman LJ. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 1994;101:198-203
   PubMed Web of Science ®Google Scholar
• Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 1994;54:5531-4
   PubMed Web of Science ®Google Scholar
• Kalebic T, Blaskesley V, Slade C, Expression of a kinase-deficient IGF-1-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing wild type IGF-1-R. Int J Cancer 1998;76:223-7
   PubMedGoogle Scholar
• Kolb EA, Gorlick R, Houghton PJ, Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-7
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Nicoletti G, Antitumor activity of the insulin-like growth factor-1 receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76
   PubMed Web of Science ®Google Scholar
• Cao L, Yu Y, Darko I, Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-48
   PubMed Web of Science ®Google Scholar
• Taulli R, Scuoppo C, Bersani F, Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-9
   PubMed Web of Science ®Google Scholar
• Armistead PM, Salganick J, Roh JS, Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. Cancer 2007;110:2293-303
   PubMed Web of Science ®Google Scholar
• Taniguchi E, Nishijo K, McCleish AT, PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-60
   PubMed Web of Science ®Google Scholar
• Barber T, Barber M, Tomescu O, Identification of target genes regulated by PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. Genomics 2002;79:278-84
   PubMed Web of Science ®Google Scholar
• Wang W, Slevin M, Kumar S, Kumar P. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int J Oncol 2005;27:1087-96
   PubMedGoogle Scholar
• Onisto M, Slongo M, Gregnanin L, Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol 2005;27:791-98
   PubMed Web of Science ®Google Scholar
• Gee MF, Tsuchida R, Eichler-Jonsson C, Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005;24:8025-37
   PubMedGoogle Scholar
• Chisholm JC, Casanova M, Geoerger B, A phase II study evaluating addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). J Clin Oncol 2010;28(15 Suppl): abstract TPS330
   Google Scholar
• Petricoin EF III, Espina V, Araujo RP, Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431-40
   PubMed Web of Science ®Google Scholar
• Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12:1007-18
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA, Initial testing (stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008;50:799-805
   PubMed Web of Science ®Google Scholar
• Kurmasheva R, Dudkin L, Billuos C, The Insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71
   PubMed Web of Science ®Google Scholar
• Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas. Expert Rev Anticancer Ther 2008;8:929-38
   PubMed Web of Science ®Google Scholar
• Carli M, Ferrari A, Mattke A, Malignant peripheral nerve sheath tumors in pediatric age: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005;23:8422-30
   PubMed Web of Science ®Google Scholar
• Casanova M, Ferrari A, Collini P, Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer 2006;106:708-17
   PubMed Web of Science ®Google Scholar
• Orbach D, Rey A, Cecchetto G, Infantile fibrosarcoma: place of chemotherapy and treatment proposals based on the European experience. J Clin Oncol 2010;28:318-23
   PubMed Web of Science ®Google Scholar
• Kushner BH, La Quaglia MP, Wollner N, Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996;14:1526-31
   PubMed Web of Science ®Google Scholar
• Bisogno G, Roganovich J, Sotti G, Desmoplastic small round cell tumor in children and adolescents. Med Pediatr Oncol 2000;34:338-42
   PubMedGoogle Scholar
• Ferrari A, Miceli R, Casanova M, Adult-type soft tissue sarcomas in pediatric age: a nomogram-based prognostic comparison with adult sarcomas. Eur J Cancer 2007;43:2691-7
   PubMed Web of Science ®Google Scholar
• Sultan I, Rodriguez-Galindo IC, Saab R, Comparing children and adults with synovial sarcoma in the surveillance, epidemiology and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009;115:3537-47
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bisogno G, Alaggio R, Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer 2008;44:1202-9
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M, Massimino M, Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol 1999;32:32-7
   PubMedGoogle Scholar
• Okcu MF, Munsell M, Treuner J, Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol 2003;21:1602-11
   PubMed Web of Science ®Google Scholar
• Pappo AS, Fontanesi J, Luo X, Synovial sarcoma in children and adolescents: the St. Jude Children's Research Hospital experience. J Clin Oncol 1994;12:2360-6
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Treuner J, Koscielniak E, Synovial sarcoma of childhood and adolescence: report of the German CWS-81 study. Cancer 1993;71:3647-55
   PubMed Web of Science ®Google Scholar
• Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer 2010: published online 8 Mar 2010, doi 10.1002/pbc.22453
   Google Scholar
• Ferrari A, Gronchi A, Casanova M, Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004;101:627-34
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Antonescu CR, Leung DH, Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000;18:2087-94
   PubMed Web of Science ®Google Scholar
• Trassard M, Le Doussal V, Hacene K, Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001;19:525-34
   PubMed Web of Science ®Google Scholar
• Antman K, Crowley J, Balcerzak SP, An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-85
   PubMed Web of Science ®Google Scholar
• Bramwell V, Rouesse J, Steward W, Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma – reduced local recurrence but no improvement in survival: a study on the European Organization for Research and Treatment of Cancer Soft Tissue Sarcoma and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-49
   PubMed Web of Science ®Google Scholar
• Santoro A, Tursz T, Mouridsen H, Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45
   PubMed Web of Science ®Google Scholar
• Ferrari A. Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther 2009;9:1541-3
   PubMed Web of Science ®Google Scholar
• Brecht IB, Ferrari A, Int-Veen C, Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr Blood Cancer 2006;46:11-7
   PubMed Web of Science ®Google Scholar
• Gronchi A, Olmi P, Casali PG. Combined modalities approach for localised adult extremity soft-tissue sarcoma. Expert Rev Anticancer Ther 2007;7:1135-44
   PubMed Web of Science ®Google Scholar
• Bramwell VHC. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol 2001;19:1235-7
   PubMed Web of Science ®Google Scholar
• Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54
   PubMed Web of Science ®Google Scholar
• Spunt SL, Ashley Hill D, Motosue AM, Clinical features and outcome of initially unresected nonmetastatic pediatric non-rhabdomyosarcoma soft tissue sarcoma. J Clin Oncol 2002;20:3225-35
   PubMed Web of Science ®Google Scholar
• Pratt CB, Maurer HM, Gieser P, Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group Study. Med Pediatr Oncol 1998;30:201-9
   PubMedGoogle Scholar
• Pappo AS, Devidas M, Jenkins J, Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23:4031-8
   PubMed Web of Science ®Google Scholar
• Ferrari A, Brecht IB, Koscielniak E, The role of adjuvant chemotherapy in surgically-resected adult-type soft tissue sarcomas of children and adolescents. Pediatr Blood Cancer 2005;45:128-34
   PubMed Web of Science ®Google Scholar
• Verweij J, Mouridsen HT, Nielssen OS, The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol 1995;20:193-201
   PubMed Web of Science ®Google Scholar
• Frustaci S, Gherlinzoni F, De Paoli A, Adjuvant chemotherapy for adult soft tissue sarcomas of extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-47
   PubMed Web of Science ®Google Scholar
• Pratt CB, Pappo AS, Gieser P, Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 1999;17:1219-26
   PubMed Web of Science ®Google Scholar
• Fata F, O'Reilly E, Ilson D, Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034-7
   PubMed Web of Science ®Google Scholar
• Penel N, Bui B, Bay JO, Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008;26:5269-74
   PubMed Web of Science ®Google Scholar
• Hensley ML, Maki R, Venkatraman E, Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-31
   PubMed Web of Science ®Google Scholar
• Maki R, Wathen JK, Patel SR, Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration study 002. J Clin Oncol 2007;5:2755-63
   Google Scholar
• Grosso F, Jones RL, Demetri GD, Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602
   PubMed Web of Science ®Google Scholar
• Dileo P, Grosso F, Casanova M, Trabectedin in metastatic Ewing's family tumors patients progressing after standard chemotherapy. J Clin Oncol 2007;25(18S): abstract 10040
   Google Scholar
• Grosso F, Sanfilippo R, Virdis E, Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20:1439-44
   PubMed Web of Science ®Google Scholar
• McArthur GA, Demetri GD, van Oosterom A, Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2003;23:866-73
   Google Scholar
• Casali PG, Messina A, Stacchiotti S, Imatinib mesylate in chordoma. Cancer 2004;101:2086-97
   PubMed Web of Science ®Google Scholar
• Heinrich MC, McArthur GA, Demetri GD, Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-203
   PubMed Web of Science ®Google Scholar
• SleiJfer S, Ray-Coquard I, Papai Z, Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009;27:3126-32
   PubMed Web of Science ®Google Scholar
• Chawla SP, Tolcher AW, Staddon AP, Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue sarcomas: update of a phase II trial. J Clin Oncol 2007;25(18S): abstract 10076
   Google Scholar
• Mita MM, Britten CD, Poplin E, Deferolimus trial 106 – a phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669). J Clin Oncol 2008;26(15S): abstract 3509
   Google Scholar
• Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2010. [Epub ahead of print]
   Google Scholar
• Schoffski P, Ray-Coquard IL, Cioffi A, Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). J Clin Oncol 2010;28(15S): abstract 10031
   Google Scholar
• Patel S, Pappo A, Crowley J, A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. J Clin Oncol 2010;27(15S): abstract 10503
   Google Scholar